{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:56:17Z","timestamp":1761872177657,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clml.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T22:02:57Z","timestamp":1679522577000},"page":"413-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2023.03.009_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.03.009_bib0002","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/cells10081961","article-title":"A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics","volume":"10","author":"Awada","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clml.2023.03.009_bib0003","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.clml.2023.03.009_bib0004","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.3390\/ijms23095242","article-title":"The role of T cell immunity in monoclonal gammopathy and multiple myeloma: from immunopathogenesis to novel therapeutic approaches","volume":"23","author":"Lagreca","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.clml.2023.03.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"22","key":"10.1016\/j.clml.2023.03.009_bib0006","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.03.009_bib0007","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.03.009_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.03.009_bib0009","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.03.009_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.03.009_bib0011","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2022-158721","article-title":"Anti-Sars-Cov-2 antibody and T-cell responses using deep T-cell receptor immunosequencing after vaccination among healthy individuals and patients with multiple myeloma or lymphoma","volume":"140","author":"Takamatsu","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","article-title":"Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma","volume":"39","author":"Aleman","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.clml.2023.03.009_bib0013","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021013714","article-title":"Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma","volume":"139","author":"Henriquez","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.03.009_bib0014","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.03.009_bib0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clml.2023.03.009_bib0016","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2023.03.009_bib0017","doi-asserted-by":"crossref","first-page":"15879","DOI":"10.3390\/ijms232415879","article-title":"Normalization of the immunological microenvironment and sustained minimal residual disease negativity: do we need both for long-term control of multiple myeloma?","volume":"23","author":"Bertuglia","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clml.2023.03.009_bib0018","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.03.009_bib0019","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2023.03.009_bib0020","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2023.03.009_bib0021","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2023.03.009_bib0022","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a Novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2023.03.009_bib0023","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade \u22653 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.03.009_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 2","key":"10.1016\/j.clml.2023.03.009_bib0025","first-page":"S46","article-title":"Prevention of infections including vaccination strategies in multiple myeloma","volume":"98","author":"Ludwig","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.03.009_bib0026","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.009_bib0027","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.009_bib0028","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","article-title":"COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network","volume":"8","author":"Ludwig","year":"2021","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.clml.2023.03.009_bib0029","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.009_bib0030","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood.2021014989","article-title":"Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy","volume":"139","author":"Terpos","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.009_bib0031","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1097\/HS9.0000000000000764","article-title":"Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy","volume":"6","author":"Ntanasis-Stathopoulos","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2023.03.009_bib0032","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccell.2022.03.013","article-title":"Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients","volume":"40","author":"Aleman","year":"2022","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.clml.2023.03.009_bib0033","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.3390\/cancers14235816","article-title":"Low spike antibody levels and impaired BA.4\/5 neutralization in patients with multiple myeloma or Waldenstrom's macroglobulinemia after BNT162b2 booster vaccination","volume":"14","author":"Rosati","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.03.009_bib0034","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2022.05.003","article-title":"Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma","volume":"40","author":"Enssle","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2023.03.009_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2021013429","article-title":"Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma","volume":"139","author":"Enssle","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2023.03.009_bib0036","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/bloodadvances.2022008530","article-title":"Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis","volume":"6","author":"Chuleerarux","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2023.03.009_bib0037","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nature Cancer"},{"issue":"23","key":"10.1016\/j.clml.2023.03.009_bib0038","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2023.03.009_bib0039","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.clml.2023.03.009_bib0040","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.03.009_bib0041","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2021-149659","article-title":"Impact of autologous hematopoietic cell transplant (HCT) followed by dendritic cell\/myeloma fusion vaccine with lenalidomide maintenance in increasing multiple myeloma (MM) immunity (BMT CTN 1401)","volume":"138","author":"Chung","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.03.009_bib0042","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.20.01706","article-title":"Vaccination as immunotherapy in hematologic malignancies","volume":"39","author":"Liegel","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.03.009_bib0043","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2020008493","article-title":"A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma","volume":"139","author":"Qazilbash","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.03.009_bib0044","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3324\/haematol.2020.259457","article-title":"Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model","volume":"106","author":"Stroopinsky","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.clml.2023.03.009_bib0045","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2023.03.009_bib0046","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"623","key":"10.1016\/j.clml.2023.03.009_bib0047","doi-asserted-by":"crossref","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"issue":"suppl 2","key":"10.1016\/j.clml.2023.03.009_bib0048","first-page":"S4","article-title":"The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception","volume":"98","author":"Dhodapkar","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.03.009_bib0049","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S2152-2650(22)00297-X","article-title":"T cell differentiation in the bone marrow during disease evolution: insights from COSMOS and integrative analysis of 317,000 single cell transcriptomes","volume":"22","author":"Foster","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.009_bib0050","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S2152-2650(22)00299-3","article-title":"Humoral immune reconstitution after quadruplet therapy, autologous hematopoietic stem cell transplant and measurable disease adapted treatment cessation in newly diagnosed multiple myeloma","volume":"22","author":"Gowda","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.009_bib0051","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S2152-2650(22)00409-8","article-title":"Altered composition of Cd8 T cell subsets over time in the bone marrow of multiple myeloma patients with long and short-term disease control","volume":"22","author":"Behsen","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2023.03.009_bib0052","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-22-0173","article-title":"Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections","volume":"4","author":"Azeem","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.clml.2023.03.009_bib0053","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:39Z","timestamp":1761871299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2152265023001064"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}